CYP1A1, GSTs and mEH polymorphisms and susceptibility to esophageal carcinoma: Study of population from a high- incidence area in north China

Table 1 Distribution of CYP1A1 genetic polymorphism in controls and subjects with cancer and different severity of lesions n(%)

	Control (n = 38)	BCH (n = 30)	DYS (n = 32)	ESCC (n = 62)
CYP1A1 3'
Wild type	12 (32)	8 (27)	9 (28)	33 (53)
Heterozygous	22 (58)	16 (53)	17 (53)	25 (40)
Homozygous variant	4 (10)	3 (10)	3 (9)	4 (6)
Heterozygous+Homozygous	26 (68)	19 (63)	20 (62)	29 (47)a
CYP1A1 exon 7
Ile/Ile	20 (53)	14 (47)	16 (50)	30 (48)
Val/Ile	16 (42)	14 (47)	15 (47)	28 (45)
Val/Val	2 (5)	2 (7)	1 (3)	4 (6)
Val/Ile + Val/Val	18 (47)	16 (53)	16 (50)	32 (52)

^aP < 0.05, vs case control group.

Table 2 Genotypes of GSTM1, GSTT1 and GSTP1 in controls and subjects with different severity of lesions and cancer n(%)

	Control (n = 38)	BCH (n = 30)	DYS (n = 32)	ESCC (n = 62)
GSTM1
+	19 (50)	16 (53)	18 (56)	35 (56)
-	19 (50)	14 (47)	14 (44)	27 (44)
GSTT1
+	18 (47)	17 (57)	15 (47)	28 (45)
-	20 (53)	13 (43)	17 (53)	34 (55)
GSTP1
Ile/Ile	24 (63)	15 (50)	15 (47)	29 (47)
Val/Ile	13 (34)	15 (50)	16 (50)	30 (48)
Val/Val	1 (3)	0 (0)	1 (3)	3 (5)
Val/Ile + Val/Val	14 (37)	15 (50)	17 (53)	33 (53)

Table 3 Slow and fast allele polymorphism of mEH in controls and subjects with different severity of lesions and cancer n(%)

	Control (n = 38)	BCH (n = 30)	DYS (n = 32)	ESCC (n = 62)
mEH slow allele
Tyr/Tyr	23 (61)	14 (47)	10 (31)	23 (37)
His/Tyr	10 (26)	13 (43)	15 (47)	22 (35)
His/His	5 (13)	2 (7)	7 (22)	17 (27)
His/Tyr+His/His	15 (39)	16 (53)	22 (69)a	39 (63)a
mEH fast allele
His/His	32 (84)	22 (73)	23 (72)	50 (81)
Arg/His	5 (13)	6 (20)	7 (22)	11 (18)
Arg/Arg	1 (3)	2 (7)	2 (6)	1 (2)
Arg/His + Arg/Arg	6 (16)	8 (27)	9 (28)	12 (19)

^aP < 0.05, vs case control group.